Advice

following an abbreviated submission:

testosterone 2% gel (Tostran) is accepted for restricted use within NHSScotland for replacement therapy with testosterone for male hypogonadism when testosterone deficiency has been confirmed by clinical symptoms and laboratory analyses.

It is an alternative to other formulations of testosterone gel, with similar costs for equivalent doses. It is restricted to use as an alternative to testosterone patches for those patients requiring a transdermal delivery system. Testosterone gel is at least as effective as testosterone patches and costs less.

Download detailed advice24KB (PDF)

Download

Medicine details

Medicine name:
testosterone 2% gel (Tostran)
SMC ID:
372/07
Indication:
replacement therapy with testosterone for male hypogonadism when testosterone deficiency has been confirmed by clinical symptoms and laboratory analyses.
Pharmaceutical company
ProStrakan
BNF chapter
Submission type
Abbreviated
Status
Restricted
Date advice published:
14 May 2007